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Introduction
The Joint Research Centre (JRC) of the European Commission 
(EC) in collaboration with the Directorate-General for Research 
and Innovation initiated an activity to define suitable indicators 
to retrospectively assess the impact of EC-funded research. To 
this aim, the JRC conducted a survey addressed to current and 
former participants of EC-funded research projects in the fields 
of Alzheimer’s disease and other dementias, breast cancer, and 
prostate cancer.
The aim of this activity is to gain insight and understanding 
related to the followings:
 ͹  How EU-funded projects have contributed to innovation and 
major scientific breakthroughs;
 ͹  How scientific results have translated into positive 
socioeconomic impacts;
 ͹  What ingredients determined the success of research 
projects;
 ͹  What scientific methods and research approaches 
underpinned the advances made.
The survey was conducted through the European Union’s 
survey platform, EU Survey, and was open from 14/02/2020 to 
31/03/2020. The URL to access the survey was disseminated 
via email, social media platforms, and through the EU Science 
Hub website1.
1 https://europa.eu/!tc47Rb
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This summary report provides a brief factual overview of the 
replies received, with information on the respondents as well 
as the number of responses and range of opinions. The replies 
gathered through this survey will help the European Commission 
assess how EU-funded research activities have contributed to 
innovation and impact. To gain a more in-depth understanding, 
follow up interviews with a number of survey respondents are 
planned. A more detailed analysis of the responses to both the 
survey and interviews will be published in a synopsis report at 
the end of the process.
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Who responded to the survey
A total of 202 participants (as of 31 March 2020) replied to 
this survey, of whom 151 received funding during Framework 
Programme (FP) H2020, 87 in FP7, 24 in FP6, and 9 in FP52.
Most of the contributors work in basic/fundamental research 
(120), followed by translational/applied research (76), clinical 
research (70), epidemiology (19), and regulatory research (6). 
An overwhelming majority of contributors work in academia 
(144), with others in industry or contract research organizations 
(39), government (22), healthcare (21), and non-governmental 
organizations (5). Most of the participants conduct(ed) research 
in the field of Alzheimer’s disease or other dementias (81), and 
breast cancer (72), followed by prostate cancer (33), with 61 
respondents selecting other.
2 Respondents may have received EU funding for more than one 
framework programme.
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Of those who responded to the survey, 17% conducted their 
research in the United Kingdom, 10% in Italy and in the 
Netherlands, 9% in Germany and in Spain, followed by France 
(7%) (Table 1).
Primary country of the  conducted research Answers
United Kingdom 34
Italy 20
Netherlands 20
Germany 18
Spain 18
France 14
Sweden 11
Belgium 9
Denmark 7
Norway 6
Switzerland 6
Austria 5
Czechia 5
United States of America 5
Other 24
Table 1: Geographical distribution of survey participants (primary 
country where they conducted their research activities)
PART 3.
What did the respondents say?
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Major Outcomes of Research 
Activities
Participants were asked about the major outcomes of their 
research. The most popular outcomes of the research activities 
include the development of a new methodology or approach 
(127), new knowledge in basic or applied field of science (91), 
new disease-related pathway or mechanism (75), new biomarkers 
(69), new diagnostic tools (65), and new therapeutic targets (60). 
Other responses include new stratification/classification strategies 
(43), new prognostic tools (35), new action improving quality of 
life (34), identification of lifestyle factor contributing to disease 
risk (27), new genetic/epigenetic factors (24), and identification of 
environmental chemicals contributing to disease risk (7) (Figure 1). 
Figure 1: Major outcomes of research activities.
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Forty percent of the respondents indicated that the outcomes 
of their research had an impact beyond their project; with 53% 
selecting an impact may be seen in the future. Three percent 
said their research did not have an impact beyond their project 
and four percent were not sure.
A large proportion of respondents (46%) implied their research 
had an impact on diagnostic or prognostic tools (94), followed by 
treatment or prevention action (57), clinical trials (48), patents 
(40), public health guidance (22), and regulatory policy actions 
(11) (Figure 2).
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Figure 2: Impact of research activities.
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Participants attributed the success of their research to a number 
of factors, most notably, collaboration with project partners 
(65%), multidisciplinarity (58%), research strategy (58%), 
and the international dimension of their project (56%). Other 
ingredients of success are outlined in Figure 3.
Figure 3: Main ingredients for success of research.
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As for the most significant challenges, 80 participants (40%) 
indicated they had difficulties in obtaining additional funding to 
continue research. Other popular responses include difficulties 
in enrolling participants (38), insufficient allocation of project 
funding (35), poor time management (22), and poor translation, 
limited public outreach, and lack of necessary materials all 
tied with 19 responses (about 10% of respondents). Fifty-
nine selected ‘other’, with common responses including time 
restraints and regulatory hurdles (Figure 4).
Figure 4: Most significant challenges encountered.
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Dissemination and Follow Up 
Activities
Survey respondents used a variety of means to disseminate their 
research outcomes, such as conferences (185), peer-reviewed 
publications (179), websites (122), lectures (115), social media 
(98), and patent registration (42). Seven did not or have not yet 
disseminated their outcomes, and 15 used other channels, such 
as the news and investors.
Notably, 73% reported that they engaged the general public to 
disseminate their research results, while 27% did not. Common 
ways to involve the public are through meetings, seminars, and 
online videos (Figure 5).
Figure 5: Efforts to engage the general public.
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The three main follow up contributions of the research 
projects are the development of new skills (131), new learning 
opportunities (112), and new employment (107).
Within two years after the end of the research project, 15% 
received additional EC funding to continue the research activity, 
32% received additional funding from a non-EC source, 26% did 
not receive any additional funding, and 41% responded that the 
question was not applicable to them3.
Moreover, two-thirds of respondents said that they changed their 
strategy, model or methodological approach in their subsequent 
research projects. In particular, 95 (47%) declared that, to increase 
multidisciplinary, they initiated collaborative efforts with different 
partners, 59 (29%) specified that they used a new methodological 
approach, and 33 (16%) a different model (Figure 6).
3 Participants could select more than one so total may be greater 
than 100%.
Figure 6: Change of strategy, model or methodological approach in subsequent research 
projects.
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Methodological Aspects 
As presented in Figure 7, respondents rated the relevance of the 
models used to their research question. Overall, less than 50% 
used in chemico assays, complex in vitro models, animal-derived 
materials or (non-human) animal models in their research.
Notably, 66% (79 out of 119) of respondents who used human 
cohorts or population studies, and 70% of respondents who used 
human-derived material (86 out of 122) considered these models 
and approaches as highly relevant to their research question(s).
Fifty-eight percent (51 out 88) of researchers who used animal 
models and 54% (50 our of 93) who used animal-derived 
materials, quoted them as highly relevant. Interestingly, only 
34% (29 out of 86) who used complex in vitro models, and 
43% (47 out of 110) of people who used in silico/computational 
approaches considered them as highly relevant.
Figure 7: Relevance attributed to the research models.
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Contributors were asked whether their model(s) was (were) 
essential to the success of their research.  Sixty-eight percent 
(86 out of 126) of respondents who used human cohorts or 
population studies, and 81% (104 out of 129) of those who made 
use of human-derived material/samples considered those models/
approaches as essential to the success of their research projects.
Seventy-two percent of users of animal models (68 out of 94) 
and/or animal-derived material (75 out of 104) considered them 
as essential to the success of their research.
Sixty-three percent of users of in silico/computational models 
(71 out of 112) rated those models as essential for their 
research success.
Finally, only half of respondents who used complex in vitro 
models (45 out 89) considered them as essential tools to the 
success of their research (Figure 8).
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Less than half of the survey participants recorded a percentage 
of their resources (both financial and human) went to studies 
involving animals (Figure 9). Thirty-six percent of them indicated 
a very low percentage (0-25%) of their financial resources 
dedicated to studies involving animals, while 15% used a more 
conspicuous proportion (76-100%) of their budget on these 
studies.
With regards to human resources, similar figures could be drawn, 
with 33% of respondents allocating a very low proportion (0-
25%) of their resources to animal studies, and 18% employing a 
relatively high percentage (76-100%).
Figure 8: Considerations about the necessity of the model to the success of the research.
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Contributors where asked to consider the currently available 
models/methods and whether or not they would consider 
changing their research approach (Figure 10).
Of the 202 survey participants, 110 (54%) felt the model they 
used is still scientifically relevant or needed and therefore they 
would not consider changing it. Thirty-eight (19%) would not 
consider changing because their model is still mandatory. Of 
those who would consider changing to another model/method, 
15 respondents (7%) would move from an animal to a non-
animal model, 14 (7%) would shift from an animal to a different 
animal model, 12 (6%) from a non-animal to an animal model, 
and 6 (less than 3%) would consider changing from a non-
animal to a different non-animal model.
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Figure 9: Percentages of financial and human resources allotted to studies involving 
animals.
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At the end of the survey, respondents were prompted to reflect 
on their experience with publishing exclusively non-animal (and 
non-clinical) research data. Nine percent reported they had an 
easy experience, while 33% reported average, and 15% said 
they had a hard time publishing non-animal research data.
Figure 10: Considerations about the possibility to modify research approaches.
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Respondents were also asked about their experience with 
receiving funding for project proposals exclusively based on non-
animal (and non-clinical) research. Six percent responded they 
had an easy experience, while 27% felt their experience was 
average, and 22% report having a hard time receiving funding 
for exclusively non-animal and non-clinical research (Figure 11).
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22%
Not applicable
45%
How was (or is) your experience with receiving funding for project 
proposals exclusively based on non-animal (and non-clinical) research?
Figure 11: Rating personal experience with obtaining funding for project proposals 
exclusively based on non-animal (and non-clinical) research.
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